Nov. 18 at 6:22 PM
Prestige Consumer Healthcare (PBH) Posts Solid 2QFY26 — EPS Beat, Strong FCF, and Accelerated Buybacks
🔹 Sales of
$274M, down 3.4% Y/Y but ahead of PBH guidance & consensus, helped by earlier-than-expected Clear Eyes inventory and strong online orders
🔹 Clear Eyes supply constraints easing — two new suppliers online; high-speed line coming via Pillar5 acquisition
🔹 Adjusted EBITDA of
$86.8M, above expectations, with solid margins
🔹PBH continues to deliver resilient performance, strong cash generation, and disciplined capital allocation — positioning the company well heading into FY26/FY27.
Read Douglas M. Lane, CFA full report for more!
$PBH #Earnings #ConsumerHealth #ClearEyes #SmallCap #Stocks #Investing #FreeCashFlow #Buybacks